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1. ABSTRACT 
 
Introduction  
Pre-operative suspicion of neuroendocrine pancreatic lesions nature arises 
both from clinical (presence and the type of secreted hormone) and 
imaging findings. However, imaging suggestion of lesion nature is based 
quite only on nodular dimension and on the presence of local and distant 
spreading. Aim of the study was to determine the nature of 
neuroendocrine pancreatic lesions by analysing lesions enhancement 
pattern at MDCT and by comparing it with histological findings, 
including the MVD. 
Materials and Methods  
We included 45 patients submitted to surgical resection for pancreatic 
neuroendocrine tumor. All preoperative CT examinations were performed 
by a multidetector CT. Post-contrastographic study included 4 phases: 
early arterial (delay 15-20”), pancreatic  (delay 35”), venous (delay 70”) 
and late phases (delay 180”). Two different patterns of enhancement were 
defined: pattern A, including lesions showing early enhancement (during 
early arterial or pancreatic phase) and a rapid wash-out; pattern B, 
including lesions with wash-in in the early arterial or pancreatic phase 
with no wash-out nor in the late phase (pattern B1), and lesions showing 
enhancement only in the venous and/or late phases (pattern B2).  
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Results  
Sixty-six lesions were detected (30 pattern A, 26 B1 and 10 B2). At 
pathology 28 lesions were adenomas, 14 borderline and 24 carcinomas: 
24/30 lesions showing pattern A were benign, 5 borderline and 1 
carcinoma; 23/36 lesions showing pattern B were carcinomas, 9 
borderline and 4 adenomas. Among the 26 B1 lesions, 13 were 
carcinomas, 9 borderline and 4 adenomas, while all 10 B2 lesions were 
malignant. Pattern A showed PPV of benignancy of 80%, and pattern B 
NPV of benignancy of 89%. MVD was evaluated in 22 lesions obtaining 
significant differences among the 3 histological and the 3 enhancement 
pattern. Significant differences between B1 and B2 malignant lesions 
existed by considering metastases (only B2 lesions) and fibrosis (all B2 
lesions).  
Conclusion  
The enhancement pattern at CT is related to MVD and the histological 
type, thus representing a further criterium for suggesting nature of 
neuroendocrine lesions. The low MVD of B2 lesions, associated with the 
presence of fibrosis, may justify the delayed enhancement of these 
lesions. 
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2. INTRODUCTION 
 
Neuroendocrine pancreatic neoplasms represent a small percentage 
among all pancreatic tumors, with an incidence of 1-1,5/100.000 cases 
[1,2]. Sporadic cases are quite unusual, representing the 1-3% of all 
pancreatic lesions [2,3,4,5] with a peak of incidence in the sixty years 
[2,6]. In patients with some hereditary syndromes (Von Hippel 
Lindau/MEN-1) such neoplasm can affect up to the 82% of patients [5,7].  
However, although rare, this diseases have different prognosis and 
therapeutic management (both medical and surgical) compared to the 
remaining pancreatic cancers, whereby require a correct identification 
and definition nature in terms of benignity / malignancy. 
On the basis of the WHO classification, among well differentiated 
neuroendocrine neoplasms also a peculiar group of tumors should be 
considered. It is the case of “borderline” lesions, that even if showing a 
benign morphological aspect, present some peculiar criteria suggesting 
possible malignant degeneration. 
Benign neuroendocrine neoplasms are in fact secreting lesions confined 
to the gland, not showing microvascular invasion, presenting a low 
mitotic index (≤ 2 mitoses/ HPF or Ki 67 ≤2%) and diameter <2cm. 
Borderline neuroendocrine neoplasms are also lesions confined to the 
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gland but they show signs of vascular invasion and increased mitotic 
index (>2/ HPF and/or Ki67>2%). Low-grade carcinomas (also called 
well differentiated neoplasms) are instead characterized by microvascular 
infiltration with locoregional or distant spreading and high mitotic index 
(2 up to 10/HPF and Ki 67 >5%). High-grade carcinomas (or low 
differentiated neuroendocrine carcinomas) are instead frequently 
metastatic at the time of diagnosis and microscopically characterized by 
small cells with loss of neuroendocrine differentiation [12].  
The prognostic value of stratifying patients into 4 risk classes according 
to the WHO classification [5] [9] has been validated in a large series with 
long follow-up [10]. In order to have more accurate prognostic 
parameters, recently experts of the European Neuroendocrine Tumor 
Society (ENETS) proposed a new staging scheme for neuroendocrine 
tumors [11] [12] based on primary tumor characteristics (such as the 
diameter of the lesions) and local invasion (T) and the presence of lymph 
node metastasis (N) or distant metastases (M) [Table I ]. 
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TABLE I. Staging of NETs of the Pancreas [14] 
 
 
 
TNM  
T-Primary Tumor 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Tumor limited to the pancreas and size <2 cm 
T2  Tumor limited to the pancreas and size 2-4 cm 
T3  Tumor limited to the pancreas and size >4 cm or invading duodenum or bile 
duct 
T4  Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or 
the wall of large vessels (celiac axis or superior mesenteric artery)  
N-Regional Lymph Nodes 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Regional lymph node metastasis 
M-Distant Metastases 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
Staging of NETs of the Pancreas 
Stage I  T1  N0  M0  
Stage IIa  T2  N0  M0  
Stage IIb  T3  N0  M0  
Stage IIIa  T4  N0  M0  
Stage IIIb  Any T  N1  M0  
Stage IV  Any T  Any N  M1  
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In addition, it was proposed to graduate neuroendocrine tumors into 3 
categories (Table II). 
 
TABLE II. Grading proposal for GEP-NETs from Rindi et al. [11] 
 
 
Even if the validity of this scheme has not been yet verified  with a 
follow-up, currently to properly classify an endocrine tumor of the gastro-
entero-pancreatic district, it is essential to refer both to the WHO criteria 
[5, 9] and the ENETS grading and staging system [13] [12]. 
At the state of the art, pre-operative suspicion of lesion nature arises both 
from clinical and imaging finding. If clinical criterium generally adopted 
in order to formulate a diagnosis of benign lesion is related to the 
presence and the type of secreted hormone, imaging suggestion of lesion 
nature is based quite only on nodular dimension and on the presence of 
local and distant spreading [11].  
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To the best of our knowledge, no previous studies have been focused on 
additional lesion imaging characteristics that may contribute to assess 
lesion biological behaviour. 
 
3. PURPOSE 
 
 
Aim of our study was to evaluate the possibility to determine the benign 
or malignant nature of neuroendocrine pancreatic neoplasms by analysing 
lesions enhancement pattern at MDCT.  
 
4. MATERIALS AND METHODS 
 
Between January 2005 and February 2012, 45 patients referred to our 
Institution because of the suspicion of neuroendocrine pancreatic 
neoplasm, arisen at a first level imaging modality or because of a 
suggestive clinical syndrome. 
Twenty seven patients were males, 18 females; average age was 59ys. 
Clinically, 11 patients complained symptoms due to hormonal secretion 
and, particularly, 9 patients complained symptoms referable to insulin 
hyperincretion, 1 to gastrine hyperincretion and 1 complained vague and 
low specific symptoms (abdominal pain and mild diarrhea).  
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Five out of 45 patients (11%) had undergone genetic analysis and resulted 
to be affected by MEN-1 syndrome; of these patients, 3 complained 
symptoms referable to insulinoma. 
All preoperative CT examinations were performed by a multidetector CT 
4 slice or 64 slice (Light Speed Plus, GE Medical System, Milwaukee 
USA;  Light Speed Plus VCT, GE Medical System, Milwaukee USA).  
The CT study was preceded by gastroduodenal hyperdistention, obtained 
by oral administration of 750/1000 ml of water and by pharmacological 
hypotonization with Buscopan® or GlucaGen®.  
CT studies were performed by acquiring basal as well as post-
contrastographic scans, after intravenous administration of high-
concentration iodinated contrast medium (Iomeron® 400) at 4 up to 
5ml/min flow rate. 
Unenhanced scans at 4 slice MDCT were acquired starting from the dome 
of the liver to the aortic carrefour, with a slice thickness and a 
reconstruction interval of 5 mm, and a pitch of  3 (High Quality-HQ 
modality) and a tube rotation speed of  0.8 sec, 120 Kv, 250 mA. 
Unenhanced scans at 64 slice MDCT were acquired starting from the 
dome of the liver to the aortic carrefour, with a slice thickness and a 
reconstruction interval of 2,5 mm, and a beam pitch 0.984:1, and a tube 
rotation speed of  0.6 sec, anode voltage 120 Kv, automatic tube current 
modulation (smart mA, noise index 17). 
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Post-contrastographic study included 4 phases: 
- Early arterial phase (delay 15-20”).  
Scans included only the pancreatic gland.  
At 4 slice CT, the applied parameters were the following: slice thickness 
1,25mm, reconstrution interval 0,6mm, pitch 6 (High Speed-HS 
modality), tub rotation speed of  0,5sec, 120 Kv, 300-350 mA. 
At 64 slice CT: were acquired starting from the dome of the liver to the 
aortic carrefour, with a slice thickness 1,25mm and a reconstruction 
interval of 0,625 mm, and a beam pitch 0.984:1, and a tube rotation speed 
of  0.6 sec, anode voltage 120 Kv, automatic tube current modulation 
(smart mA, noise index 21) 
 
- Pancreatic phase (delay 35”). This phase was acquired during the same 
inspiratory apnoea of the early arterial.  
At 4 slice CT, scans were acquired from the mesenteric root  up to the 
dome of the liver, and the applied parameters were: slice thickness 
2,5mm, reconstruction interval 1,25mm, pitch 6 (HS), tube rotation speed 
0,5 sec, 120 kV, 300-330 mA. 
At 64 slice CT, were acquired starting from the dome of the liver to the 
aortic carrefour, with a slice thickness 1,25mm and a reconstruction 
interval of 0,625 mm, and a beam pitch 0.984:1, and a tube rotation speed 
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of  0.6 sec, anode voltage 120 Kv, automatic tube current modulation 
(smart mA, noise index 21) 
 
- Porto-venous phase (delay 70”). Scans were acquired from the dome of 
the liver to the aortic carrefour. 
At 4 slice CT, the applied parameters were: slice thickness 2,5mm, 
reconstruction interval 1,25mm, pitch 3 (HQ), tube rotation speed of 0,8 
sec, 120 Kv, 300-330 mA. 
At 64 slice CT were acquired with a slice thickness 1,25mm and a 
reconstruction interval of 0,625 mm, and a beam pitch 0.984:1, and a tube 
rotation speed of  0.6 sec, anode voltage 120 Kv, automatic tube current 
modulation (smart mA, noise index 21) 
 
- Late phase (delay 180”). Scans were acquired from the dome of the 
liver to the mesenterial root. 
At 4 slice CT the applied parameters were: slice thickness 2,5mm, 
reconstruction interval 1,25mm, pitch 3 (HQ), tube rotation speed 0,8 sec, 
120 Kv, 300-330 mA, while at 64 slice CT scans were acquired from the 
dome of the liver to the aortic Carrefour, with a slice thickness 1,25mm 
and a reconstruction interval of 1,25 mm, and a beam pitch 0.984:1, and a 
tube rotation speed of  0.6 sec, anode voltage 120 Kv, automatic tube 
current modulation (smart mA, noise index 21). 
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At MDCT, we performed a qualitatively analysis of the post-
contrastographic behaviour in different subsequent phases. 
Particularly, two different patterns of enhancement were defined (Fig. 1):  
Pattern A 
➢ including lesions showing an early enhancement (during early 
arterial or pancreatic phase) and a rapid wash-out, thus resulting isodense 
to the parenchyma in the venous/late phases (Fig. 2) 
Pattern B  
➢ including lesions showing wash-in in the early arterial or 
pancreatic phase with no wash-out nor in the late phase (pattern B1), and 
lesions showing enhancement only in the porto-venous and/or late phases 
(pattern B2)  (Fig. 3, 4).  
At MDCT, the greatest lesion dimension was also measured.  
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Fig. 1-Patterns of enhancement. After the iv injection of contrast 
material 3 different curves of enhancement were identified: pattern A: 
enhancement in the early arterial or pancreatic phase and a rapid wash-
out; pattern B1: wash-in in the early arterial or pancreatic phase with no 
wash-out nor in the late phase; pattern B2: enhancement only in the 
porto-venous and/or late phases. 
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Fig. 2-Pattern A. After contrast medium injection, the neuroendocrine 
lesion located in the tail of the pancreas shows a vivacious enhancement 
during the early arterial phase; the wash-in is still evident during the 
pancreatic phase, while the lesion appears as isodense in the porto-venous 
and late phase. 
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Fig. 3-Pattern B1. After contrast medium injection, the neuroendocrine 
pancreatic neoplasm shows vivacious enhancement yet during the early 
arterial and pancreatic phase; the lesion still appears as hyperdense in 
respect to the surrounding parenchyma  in the venous and late phases. 
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Fig. 4- Pattern B2. The lesion of the pancreatic head appears as 
isodense in respect to the parenchyma in the early arterial and 
pancreatic phases. Only during the porto-venous phase the lesion shows 
a mild enhancement, that becomes really evident in the late phase. 
 
Data obtained from MDCT examination were then related to those 
obtained at histology after surgical resection, including the lesion 
dimension and the Ki67 value (according to the WHO classification 
system), and the microvascular density-MVD. 
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In order to be observed by light microscopy, the tissues were cut into a 
rotary microtome to obtain sections of 1-5 µm. 
For each sample, a section recovered by collection tank on a glass slide 
with electrostatic charge was obtained; this slide was used for 
immunohistochemical staining of CD34. 
To analyze and process the data extracted from each histological sample, 
we used a dedicated system of acquisition and processing (Olympus BX-
51, software AnalySIS^B). This system is composed of a microscope and 
a computer connected with a high resolution digital camera (resolving 
power: 12 MegaPixel color). The images, seen under the microscope, can 
be acquired with variable magnification (4X, 10X, 20X and 40X) and 
processed at computer. The system, thanks to a micrometric calibration 
made at the time of installation, allows to directly obtain the real 
measurements of histological sections. 
Each sample was evaluated by using two different methods: 
➢ Evaluation of the DMV by counting number of vessels: 
for each case, 6 hypervascular fields were evaluated, at a magnification of 
20X, obtaining a surface area of 0.588 mm2 for each field. For each field 
vessels (corresponding to the brown spots after CD34 staining) were 
counted. The total area analyzed for each sample was 3.528 mm2. 
➢ Automatic computerized analysis of specimens: 
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The program analySIS ^ B enables to automatically evaluate the relative 
percentage of surface vessels, by calculating the ratio between the CD34 
stained area and the total area of the examined field.   
 
5. RESULTS 
 
 
At MDCT, 66 lesions were detected in 45 patients. Three patients 
affected by MEN-1 syndrome, presented 3, 5 and 15 lesions respectively 
and 2 patients, not affected by any familiar genetic syndrome, showed 2 
and 3 lesions. 
MDCT posed the suspicion of metastatic involvement of the liver in 7 out 
of 45 cases (16%). 
At MDCT, 30 out of 66 (45%) lesions showed a pattern of type A; 
diameters of such lesions ranged between 5 and 30mm (average 
maximum diameter at CT-adCT: 11mm).   
Thirty-six out of 66 (55%) lesions showed instead pattern B; diameters of 
such lesions ranged between 5 and 100mm (adCT: 37mm); 26 lesions 
presented pattern B1 (diameter ranging between 5 and 80mm; adCT 
32mm) and 10 pattern B2 (ranging between 15 and 100mm; adCT 
47mm).  
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All patients underwent curative surgery: 5 patients underwent tumoral 
enucleation, 13 pancreaticoduodenectomy, 22 left pancreatectomy, 4 total 
pancreatectomy and 1 regional pancreatectomy. 
In the 7 cases suspected to have hepatic metastases at MDCT, a focused 
resection of the hepatic lesion was performed in order to obtain a 
pathological analysis. 
Pathology assessed the neuroendocrine nature of all 66 lesions identified 
at MDCT. Particularly, 28 out of 66 (43%) lesions were classified as 
benign neuroendocrine neoplasms (adenomas), 14 out of 66 (21%) as 
borderline neoplasms and 24 out of 66 (36%) as low grade carcinomas. 
Histology confirmed the presence of liver metastases in all the 7 cases 
submitted to liver resection; all these patients were affected by low grade 
carcinomas. 
At pathology (Table III), 24 out of 30 lesions showing pattern A (80%) 
resulted to be adenomas (diameters ranging between 5 and 15mm; 
average maximum diameter at histology-adH: 9mm), 5 (17%) borderline 
neoplasms (10-22mm; adH 15mm) and 1 resulted to be a low grade 
carcinoma (maximum diameter: 10mm). The adCT of benign, borderline 
and malignant lesions showing pattern A was 9mm, 18mm and 12mm 
respectively. 
Twenty-three out of 36 lesions (64%) showing pattern B resulted to be 
low grade carcinomas (5-70mm; adH 42mm), 9 (25%) borderline 
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neoplasms (7-28mm; adH 16mm) and 4 benign lesions (5-20mm; adH 
13mm). The adCT of benign, borderline and malignant lesions showing 
pattern B was 14mm, 17mm and 45mm respectively. 
More in detail, among lesions showing pattern B1, 13 out of 26 (50%), 
resulted to be low grade carcinomas, 9 (35%) borderline neoplasms and 4 
(15%) adenomas. All the 10 lesions (100%) showing pattern B2 resulted 
to be low grade carcinomas. 
Overall, pattern A showed a positive predictive value (PPV) in assessing 
benignancy of 80%, while pattern B showed a NPV in assessing 
benignancy of 89% and a PPV of malignancy of 64%.   
 
TABLE III 
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Regarding the correlation between MDCT and histology about lesions 
dimensions, results are shown on Graph. 1 and Graph. 2. We found a 
good correlation both in case of lesions with pattern A (R=0,79) and 
pattern B (R=0,85); the correlation resulted to be excellent (R=0,91) by 
considering together lesions resulting hyperdense in early phases (pattern 
A and B1) (Graph. 3). 
 
 
 
 
Graph. 1- Pattern A: dimensional correlation between CT and pathology 
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Graph. 2- Pattern B: dimensional correlation between CT and pathology 
 
 
 
 
Graph. 3-Pattern A and B1: dimensional correlation between CT and 
pathology 
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The evaluation of the MVD was performed in 22 out 66 lesions (30%), in 
particular 4 adenomas, 5 borderline lesions and 13 carcinomas.  
The distribution of these lesions tumors according to their enhancement 
pattern is show in Graph. 4. 
In each case, the total analyzed area was 3,528 mm2. 
 
 
Graph. 4- Distribution of lesions according to their enhancement pattern 
 
The graphs below (Graph. 5-6) show the average MVD values of lesions, 
grouped according to their enhancement pattern at CT; differences among 
the 3 groups were statistically significant, both by counting vessels (p = 
0,0194) and by using the automatic system (p = 0.0401). 
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Graph.5- Radiological grading of MVD: number of vessels 
 
 
Graph.6-Radiological grading of MVD: surface of vessels 
 
By grouping lesions according to their histological type, instead, 
differences among the 3 groups were not statistically significant, both by 
 26 
counting vessels (p = 0,210) and by using the automatic system (p = 
0.0818) (Graph. 7-8). 
 
 
 
Graph.7-Pathological grading of MVD: number of vessels 
 
 
Graph.8-Pathological grading of MVD: surface of vessels 
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However, significant differences were obtained by considering together 
non-carcinomatous lesions (adenomas and borderline lesions, 9 cases); 
differences in the DMV were statistically significant, both by counting 
the number of the vessels (p = 0.0232) and by evaluating the relative 
surface of the vascular tissue (p = 0.0056) (Graph. 9-10). 
 
 
 
Graph.9-MVD of adenomas/borderline lesions vs WDC: number of 
vessels 
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Graph.10-MVD of adenomas/borderline lesions vs WDC: surface of 
vessels 
 
Graphs 11 and 12 summarize Ki67 values distribution according to the 
histological type and the MDCT pattern. The average value of Ki67 was 
3.  
 
Graph.11-Ki 67 values: MDCT patterns 
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Graph.12-Ki 67 values: histological type 
 
Ki67 values ranged between 0,5 and 1,5 in adenomas and between 0,5 
and 10 in carcinomas; in all 5 borderline lesions Ki67 value was 1.   
Considering the radiological patterns, the values of Ki67 were between 1 
and 1,5 for pattern A, between 0,5 and 7 for pattern B1 and  between 0,5 
and 10 for pattern B2, respectively. Interestingly, among B1 lesions, the 2 
lesions with Ki67 value <1 (0,5) were benign, the 3 lesion with Ki67 
value =1 were borderline and all 5 lesions with Ki67 values ≥2 were 
malignant (p = 0,0441).  
The correlation between the radiological pattern and the corresponding 
values of Ki67 was practically significant (p=0.0864), while we obtained 
significance (p=0,0395) by correlating Ki67 values and pathological 
subtype.  
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In addition, we compared the 13 carcinomas included in this series, by 
analyzing presence fibrosis, lymph node metastasis and distance 
spreading. The comparative examination of this group revealed 
statistically significant differences between B1 and B2 malignant lesions 
(p = 0.0003). In particular, lymph node metastases were present in 3/5 B1 
carcinomas and in 6/8 B2 carcinomas; distant metastases were present in 
7/8 B2 carcinomas and only in 1/5 B1 carcinoma. Regarding the presence 
of fibrosis, it was demonstrable in 2/5 B1 carcinomas, while, 
interestingly, in all B2 carcinomas, and it was associated with the 
presence of macrophages filled with hemosiderin pigment; these 
pathological findings are typical of a more aged disease. This results are 
summarized in Graph. 13. 
 
Graph.13-Characteristic of WDC group 
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6. DISCUSSION 
 
The role of imaging in the evaluation of neuroendocrine pancreatic 
neoplasms includes the localization of functioning neoplasms, the 
differential diagnosis with other pancreatic lesions, the identification of 
signs of malignancy and the loco-regional staging, that may help in 
suggesting the best therapeutic approach [15,16]. Particularly, in case of 
functioning neuroendocrine neoplasms, the clinical history and 
haematochemical data play a pivotal role in the diagnosis and imaging is 
mainly requested to identify and localize the neoplasm. 
Not functioning neuroendocrine pancreatic neoplasms are instead 
frequently late diagnosed, almost in advanced stage, because of 
symptoms due to the mass effect or to loco-regional or distant spreading. 
In this case, imaging is mainly requested to give an accurate stadiation 
and to pose a reliable differential diagnosis with other pancreatic 
malignancies, especially with ductal adenocarcinoma, because of the 
different therapeutic approach and the significantly different prognosis 
[10].   
In fact, not secreting neoplasms show a better prognosis and are 
frequently resectable in respect to other primary malignancy, even if 
turning out to be malignant in more than 50% of cases and presenting 
distant spreading at the time of diagnosis. It is then fundamental to obtain 
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a correct diagnosis of nature and an accurate evaluation of the secondary 
spreading in order to choose the best therapeutic approach. 
Thanks to advanced imaging techniques, nowadays the detection of a 
small neuroendocrine neoplasm shows a high sensitivity [11-13, 17, 18-
20] ranging between the 47 and the 72% [11, 12], even if it decreases 
sensibly (12%) in the detection of subcentimetric neoplasms. Many 
studies have been conducted in order to define the best diagnostic 
protocol at MDCT to identify the lesion [12, 13, 16, 17, 23-26].  
At the state of the art, the best available criteria to formulate a suspicion 
of benignancy/malignancy of a neuroendocrine pancreatic lesion are the 
presence of a clinical syndrome, the lesion dimension (according to the 
WHO classification system) and the presence of signs of local or distant 
invasion at imaging. 
Previous studies about the morphological presentation of neuroendocrine 
pancreatic neoplasms at MDCT reported that functioning benign 
neoplasms are usually small and homogeneously hypervascular [10, 21, 
25], showing a wash-out yet in the porto-venous phase, while malignant 
tumors show generally greater dimensions, necrosis and calcifications 
[15, 25, 26] and a less homogeneous enhancement, particularly during the 
arterial phase [10, 27, 26, 28].  
Anyway, when signs of locally advanced or metastatic involvement lack, 
the characterization in terms of nature is still challenging [29]. 
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Recent studies demonstrate that perfusion CT is a feasible technique to 
assess tissue perfusion in patients with endocrine tumors of the pancreas. 
In particular a study of D’Assignies (2009) shows that tumor blood flow 
values are strongly correlated with tumoral MVD (p<0,001) and that 
perfusion parameters well correlate with a number of other prognostic 
indicators of lesion nature (35). 
Aim of our study has been to assess the role of MDCT in the 
characterization of neuroendocrine pancreatic neoplasms in terms of 
benignancy/malignancy by analysing the lesion post contrastographic 
enhancement. 
We applied a MDCT study protocol that included four subsequent phases 
after contrast medium injection, acquiring scans in the early arterial, 
pancreatic and venous phase, as reported in literature [12, 13, 17, 33, 34, 
16, 21-24]; however at the end of the study (180”) we added a fourth late 
phase.  
By analysing the enhancement behaviour of different lesions in all the 
post contrastographic scans in respect to the surrounding pancreatic 
parenchyma, focusing on the time of wash-in and wash-out, we identified 
two different patterns, A and B. Lesions with pattern B were 
subsequently classified into two patterns (B1 and B2) depending on the 
time of enhancement. 
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The major difference between pattern A and B consisted in the 
persistence of enhancement during the venous and late phases (B1) or in 
the evidence of enhancement only during the venous and/or late phase 
(B2). 
The introduction of many subsequent post contrastographic acquisitions 
for the identification and characterization of neuroendocrine pancreatic 
neoplasms found its reason in the characteristic hypervascularity of such 
tumors [18, 31, 32]. In fact, insular cells, even if representing only the 1-
2% of the entire parenchyma, receive a rich vascularization (10-20% of 
the entire pancreatic arterial flow), thanks to the presence of windowed 
capillaries, whom morphology and distribution ensure a rapid capillary 
exchanges in normal conditions [19].  
In neuroendocrine neoplasms, it is possible to find out a different  
organization of the vascularization, due to a strong angiogenetic impulse; 
in small benign lesions, the multiple neovessels maintain a regular 
architecture and distribution, while in malignant nodules, because of a 
disorganized angiogenesis, neovessels result to be dysmorphic, thus 
leading to an abnormal lesion in and out flow [18, 30, 31, 32]. This 
different vascular structure is the main reason of the different post-
contrastographic behaviour of malignant neoplasms, as reported in 
literature [12, 18, 26]. On the basis of these statements, it is then possible 
to affirm that the persistence of contrast enhancement during a late phase 
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may be considered as a prognostic sign of malignancy, being related to 
the lack of organization of the vascular structures and to the thrombosis 
into the perilesional capillaries, that delays the normal lesion wash-out 
[12, 18, 20]. 
In fact, in our study, 28 (43%) lesions resulted to be benign at histology, 
24 (36%) malignant and 14 (21%) borderline. Particularly, 24 out of 30 
lesions (80%) showing pattern A resulted to be benign (adH: 9mm), while 
only 1 (3%) resulted to be a low grade carcinoma. Regarding the 36 
lesions showing pattern B, 23 (64%) resulted to be low grade carcinomas 
(adH: 45mm) and, particularly, all the 10 lesions (100%) showing pattern 
B2 at MDCT. Overall, pattern A showed then a PPV of 80% in predicting 
benignancy, while pattern B showed a NPV of 89% in suggesting 
malignancy and PPV in predicting malignancy of 64%. 
On the basis of our results, the enhancement patterns resulted to well 
correlate with the greatest diameter in predicting lesion nature. 
Average diameters of lesions showing pattern A at MDCT was 11mm 
and, particularly average diameters of 24 lesions with pattern A resulting 
to be benign nodules was 9mm, both at histology and MDCT. Average 
diameters of lesions showing pattern B at MDCT was 37mm and, 
particularly average diameters of malignant ones (23 cases) was 45mm at 
MDCT and 41mm at histology. 
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Particularly, at histology, all the 28 benign lesions showed a maximum 
greatest diameter <2cm, while the average diameter of low grade 
carcinomas was greater (41mm); only in one case, a low grade carcinoma 
showed a greatest diameter of 12mm and a pattern of type A. In this case, 
the lack of concordance has been justified on the basis of pathological 
analysis, that showed the absence of necrotic areas within the neoplasm 
and the absence of vascular abnormalities and thrombosis, probably due 
to the moderate mitotic activity of neoplastic cells. 
Results about correlation between lesion dimensions at MDCT and 
histology (Graph 1-2) showed an excellent correlation (R=0.79) in case of 
lesions with pattern A, a very good (R=0,85) correlation between 
measurements in lesions with pattern B and excellent correlation 
(R=0,91) considering A and B1 patterns together (Graph 3). 
The better correlation between measurements in cases of lesions showing 
pattern A and B1 may be justified because of an improved delineation of 
nodular edges thanks to the strong and more homogeneous enhancement. 
In our study we have also evaluated if the post-contrastographic patterns 
at MDCT could be related to microvascular density (MVD). 
Some Autors demostred the correlation between MVD (expression of 
vessels average number per surface unit) and lesions malignancy degree: 
so benign neoplasms were more vascularized than carcinomas. 
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Our results are similar to those obtained by Couvelard, despite our 
analysis include a wider surface of tumor (+33%) (Table IV). 
 
Authors Tumors 
type 
Parameter Fields 
number 
Fields 
surface 
Delta 
Couvelard 2005    NET     CD34      6    0,442     - 
Our study    NET     CD34      6    0,588  +33% 
 
TABLE IV 
 
In addition, even using the automated system to assess the MVD as 
relative vascular area, we obtained a statistically significant difference in 
particular between benign and borderlinevs malignant lesions. According 
to the pattern of enhancement, we obtained a statistically significant 
difference in the MVD between the three groups (p = 0.0401), and in 
particular cases with B2 behavior has been shown to have the lowest 
values of the MVD. 
Considering the correlation between radiological patterns and Ki67 
values, we obtained a practical significance (p=0.0864); however, 
interestingly, all A lesions had Ki67 values <2 and, among B1 lesions, 
both lesions with Ki67 value <1 (0,5) were benign, the 3 lesion with Ki67 
 38 
value =1 were borderline and all 5 lesions with Ki67 values≥2 were 
malignant (p=0.0441) .  
Also, the histological analysis showed peculiar characteristics in 
carcinomas with B2 pattern, with respect to malignant B1 lesions, such as 
the presence of fibrosis (100% of the cases B2), lymph node metastases 
(75% cases B2) and distance spreading (88% of cases B2 and only one 
B1). 
These data seem to justify the malignant lesions radiological behaviour, 
with a wash-in only in the late stages, due to the low MVD and the 
presence of numerous areas of fibrosis. The well-differentiated 
carcinomas (B1), that are less aged than B2 carcinomas, are lesions that 
maintain the hypervascularization of lesions with pattern A (characterized 
by high MVD) and that have lower amount of fibrosis than B2 lesions, 
thus showing an intermediate behavior, with early enhancement, 
persistent in late phases. 
 
7. CONCLUSIONS 
In conclusion, MDCT may suggest the nature of a neuroendocrine 
pancreatic neoplasm and particularly, the lesion post-contrastographic 
pattern may represent a further criterium for suspecting lesion 
malignancy. On the basis of our results, in presence of a lesion showing 
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pattern A it is reasonable to suspect lesion benignancy, while lesions 
showing enhancement in the late phase, as showed in pattern B lesions, 
should be considered as suspected for not benignancy. 
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